Podcast
The New Array of Choices in Prostate Cancer—What’s Best for Your Patients? Part 2
Release Date: February 10, 2022
Expiration Date: February 9, 2023
CE/CME Credit Hours: 0.50
Pharmacology Credit Hours: 0.50
Begin »
Program Overview
Program Description
Prostate cancer is the most frequently diagnosed cancer in men in the United States and the second leading cause of cancer mortality in this group. In recent years, a range of new and emerging therapeutic agents offer new options for healthcare providers and their patients across the continuum of this disease. This second of 2 podcasts offers an overview of current strategies and best approaches in treatment selection and adverse event management for patients with prostate cancer, as well as expert case discussion with Rana McKay, MD, Arjun Balar, MD, and Terran Simms, MSN, ACNP-C, CNN-BC, COCN.
To access episode 1, click here.
Format
Podcast
Learning Objectives
After completing this activity, participants should be better able to:
- Summarize available and emerging agents across the continuum of prostate cancer
- Apply efficacy and safety evidence, molecular testing, and guideline recommendations to develop treatment plans for patients with prostate cancer
- Implement strategies to identify and manage adverse events associated with treatment of prostate cancer
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Arjun Balar, MD
- Associate Professor of Medicine
- Division of Hematology/Oncology
- NYU Langone Health
- New York, New York
Rana R. McKay, MD
- Associate Professor
- Department of Medicine
- Divisions of Hematology/Oncology and Urology
- University of California San Diego
- San Diego, California
Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN
- Nurse Practitioner
- Department of Urology
- University of Virginia
- Charlottesville, Virginia
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until February 9, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA Course Advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.
This program is cosupported by educational grants from Astellas and Pfizer; Bayer HealthCare Pharmaceuticals Inc.; and Seagen Inc.
This activity is supported by educational grants from Astellas and Pfizer and Bayer HealthCare Pharmaceuticals Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
Dr McKay: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento Therapeutics, and Tempus.
Ms Sims: consulting fees: Coloplast.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Listen to the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
The estimated time to complete this activity is 0.50 hours.
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.
Release date: February 10, 2022
Expiration date: February 9, 2023
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103421-POD1B